The phase I clinical trial protocol discussion meeting for Shanghai Yingli Pharmaceutical’s novel immune-oncology agent YL-13027 has been successfully held in Shanghai
Nov. 14, 2018, Shanghai Yingli Pharmaceutical Co., Ltd. (“Yingli Pharma”) announces today that the phase I clinical trial protocol discussion meeting for YL-13027, a novel immune-oncology agent independently developed by Yingli Pharma, has been successfully held at Shanghai Oriental Hospital. Two well-known experts from Shanghai Oriental Hospital, Professor Jin Li and Professor Ye Guo, attended the discussion. The participating experts had thorough discussion and in-depth analysis on the preclinical data package of YL-13027 and the scientificity, feasibility and the safety of the clinical protocol. The valuable suggestions provided by the experts lay a good foundation for ensuring a scientific, specification and feasible clinical trial protocol. The clinical trial is led by Professor Jin Li from Shanghai Oriental Hospital.
YL-13027 is a novel transforming growth factor-β receptor 1 (TGFβR1) inhibitor, which is intended for the treatment of solid tumors, multiple myeloma and myelodysplastic syndrome. In preclinical studies, YL-13027 demonstrated good efficacy in inhibiting tumor growth via increasing the number of tumor-infiltrating lymphocytes in tumors. YL-13027 also enhanced the anti-tumor efficacy of anti-PD-L1 antibody. It is expected to have great potential as a cancer immuno-therapeutics.